Business Segments · Reclassification to: cost of sales
MedSurg and Neurotechnology: — Reclassification to: cost of sales
Stryker MedSurg and Neurotechnology: — Reclassification to: cost of sales decreased by 41.6% to $1.29B in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 39.2%, from $2.12B to $1.29B. This is a positive signal — lower values indicate better performance for this metric.
Analysis
StatementSegment
CategoryProfitability
SignalLower is better
VolatilityModerate
First reportedQ1 2016
Last reportedQ1 2026May 11, 2026
Rolls up toTotal Cost of Revenue
How to read this metric
An increase in reclassified costs may compress gross margins, while a decrease suggests improved cost allocation or operational efficiency.
Detailed definition
Captures specific expenses or costs previously categorized elsewhere that have been reallocated to the cost of sales for...
Peer comparison
Common in companies with complex accounting adjustments or evolving cost-accounting standards.
Metric ID:
syk_segment_medsurg_and_neurotechnology_reclassification_to_cost_of_salesHistorical Data
37 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q1 '22 | Q2 '22 | Q2 '22 | Q3 '22 | Q3 '22 | Q4 '22 | Q4 '22 | Q1 '23 | Q1 '23 | Q2 '23 | Q2 '23 | Q3 '23 | Q3 '23 | Q4 '23 | Q4 '23 | Q1 '24 | Q1 '24 | Q2 '24 | Q2 '24 | Q3 '24 | Q3 '24 | Q4 '24 | Q4 '24 | Q1 '25 | Q1 '25 | Q2 '25 | Q2 '25 | Q3 '25 | Q3 '25 | Q4 '25 | Q4 '25 | Q1 '26 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $1.52B | $1.52B | $1.66B | $1.54B | $1.16B | $1.67B | $1.16B | $1.7B | $1.16B | $1.97B | $1.16B | $1.76B | $1.22B | $1.82B | $1.22B | $1.75B | $1.22B | $2.11B | $1.22B | $1.91B | $1.24B | $2.01B | $1.29B | $1.98B | $1.31B | $2.26B | $1.48B | $2.12B | $1.18B | $2.18B | $1.41B | $2.21B | $1.43B | $2.54B | $1.7B | $2.21B | $1.29B |
| QoQ Change | — | -0.3% | +9.1% | -6.9% | -24.8% | +43.8% | -30.5% | +46.4% | -31.7% | +69.6% | -41.0% | +52.0% | -30.8% | +48.9% | -32.8% | +43.6% | -30.4% | +73.3% | -42.3% | +56.7% | -35.2% | +62.0% | -35.8% | +53.6% | -33.6% | +72.3% | -34.5% | +43.2% | -44.6% | +85.6% | -35.2% | +55.9% | -35.3% | +78.3% | -33.3% | +30.2% | -41.6% |
| YoY Change | — | — | — | — | — | +9.5% | -23.8% | +11.8% | -23.6% | +18.7% | -30.0% | +14.3% | -20.9% | +8.9% | -26.9% | +3.2% | -28.2% | +7.4% | -38.0% | +8.4% | -29.7% | +10.5% | -29.1% | +12.9% | -25.0% | +7.1% | -29.8% | +11.1% | -38.5% | +8.7% | -29.5% | +11.5% | -27.9% | +12.4% | -25.0% | +4.1% | -39.2% |
Range$1.16B – $2.54B
CAGR-1.8%
Avg YoY Growth-9.5%
Median YoY Growth-8.9%
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Stryker's medsurg and neurotechnology: — reclassification to: cost of sales?
- Stryker (SYK) reported medsurg and neurotechnology: — reclassification to: cost of sales of $1.29B in Q1 2026.
- How has Stryker's medsurg and neurotechnology: — reclassification to: cost of sales changed year-over-year?
- Stryker's medsurg and neurotechnology: — reclassification to: cost of sales decreased by 39.2% year-over-year, from $2.12B to $1.29B.
- What does medsurg and neurotechnology: — reclassification to: cost of sales mean?
- Costs moved into the cost of goods sold category to better reflect direct production expenses.